Bill Oxford/iStock via Getty Images
CRISPR Therapeutics (NASDAQ:CRSP) drug candidate CTX-110 is likely to be the next CRISPR-based gene therapy to be globally launched, possibly towards the end of 2025, according to a report by GlobalData.
The product is currently in Phase 2 development for B-cell malignancies. Despite CRISPR’s success with the gene therapy Casgevy, which recently won FDA approval, GlobalData sees CTX-110 as only having a 48% chance of advancing to Phase 3 and a 31% chance of approval.
According to GlobalData, only 24 CRISPR-based drugs are in Phase 2 trials, with 88% of such drugs in earlier-stage or preclinical development.
CRISPR and partner Vertex Pharmaceuticals (VRTX) made history earlier this month when Casgevy became the first FDA-approved treatment utilizing CRISPR gene-editing technology. The product was approved for the treatment of sickle cell anemia and is awaiting approval for transfusion-dependent thalassemia.
